People: Adial Pharmaceuticals Inc (ADIL.OQ)

ADIL.OQ on NASDAQ Stock Exchange Capital Market

21 Sep 2020
Change (% chg)

$-0.04 (-3.03%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Stilley, William 

Mr. William B. Stilley III serves as President, Chief Executive Officer, Director of the Company. Mr. Stilley was the Vice President, Business Development & Strategic Projects at Clinical Data, Inc. (Nasdaq: CLDA). At Clinical Data, Inc., Mr. Stilley worked on licensing and M&A transactions and was involved in management of Phase 3 clinical trials, production of Viibryd ® for initial commercial launch of the product, and sourcing drug product and drug substance for the Phase 3 clinical trials of the company’s vasodilator drug for myocardial stress imaging. From February 2002, Mr. Stilley was the COO and CFO of Adenosine Therapeutics, LLC where he ran the internal operations of the company, including research and development, and all financing activity, until the sale of its principal assets were acquired by Clinical Data, Inc. in August 2008. Deals closed include, without limitation, financings, licenses or acquisition agreements with Johnson & Johnson, Novartis, Santen Pharmaceuticals, Epix Pharmaceuticals, CombinatoRx, ATEL Ventures, Medical Predictive Sciences Corporation, and Novartis Ventures. Mr. Stilley has advised both public and private companies on financing and M&A transactions, has been the interim CFO of a public company, the interim Chief Business Officer of Diffusion, and the COO and CFO of a number of private companies. Before entering the business community, Mr. Stilley served as Captain in the U.S. Marine Corps. Mr. Stilley has an MBA with honors from the Darden School of Business and a B.S. in Commerce/Marketing from the McIntire School of Commerce at the University of Virginia. He has guest lectured at the Darden School of Business in two courses on the management of life science companies and serves on the Board of Directors of Virginia BIO, the statewide biotechnology organization. He also holds patents for Stedivaze®, which is currently in Phase 3 clinical development.

Basic Compensation

Total Annual Compensation, USD 381,695
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 1,984,690
Fiscal Year Total, USD 2,366,390

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --